

ASX: CVB

23 August 2023

## CurveBeam AI presenting at E&P Small Cap Healthcare Conference

**CurveBeam AI will be presenting at the E&P Small Cap Healthcare Conference, 12-13 September 2023 – please find attached the investor deck for the conference.**

**Ura P Auckland  
Company Secretary  
For the Board of Directors**

< ENDS >

### About CurveBeam AI Limited

CurveBeam AI (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

### Investor / media enquiries

Matthew Wright  
NWR Communications  
+61 (0) 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)



# E&P SMALL CAPS HEALTHCARE CONFERENCE

INVESTOR PRESENTATION  
September 2023



# DISCLAIMER

## Introduction

THIS DOCUMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS DOCUMENT IS NOT AN OFFER OR INVITATION TO BUY OR SELL SECURITIES.

This presentation has been prepared by CurveBeam AI Limited (ACN 140 706 618) (ASX:CVB) (**CurveBeam** or the **Company**) and contains summary information about CurveBeam and the business conducted by it as at 12 September 2023. The information in this presentation is for informational purposes only, does not purport to be complete and is not a prospectus, product disclosure statement or other disclosure document for the purposes of Chapter 6D or Part 7.9 of the Corporations Act 2001 (Cth) (**Act**) or other offer document under Australian law or the law of any other jurisdiction.

The distribution of this document outside of Australia may be restricted by law and any such restrictions should be observed. This document may not be distributed or released to any person in the United States.

As further detailed below, none of CurveBeam, nor its advisers (**Advisers**) nor their respective affiliates, related bodies corporate (as defined in the Act) or security holders and their respective directors, officers, employees, partners, representatives, consultants, agents or advisers (each a **Limited Party** and together, the **Limited Parties**) guarantees or make any representation or warranty to, or takes responsibility for, the accuracy, reliability or completeness of the information contained in this presentation, to the **Recipient** of this document (you or the Recipient), and nothing contained in this document is, or may be relied upon as, a promise or representation, whether as to the past or future. To the maximum extent permitted by law, each Limited Party disclaims any liability for any loss arising from the use of information including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation.

## Not an offer or financial product advice

The information contained in this presentation is for informational purposes only and should not be considered, and does not contain or purport to contain, an offer, invitation, solicitation or recommendation with respect the purchase or sale of any securities in CurveBeam nor does it constitute legal, taxation, financial product or investment advice. The general information in this presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Recipients of the presentation must undertake their own independent investigations, consideration and evaluation. By accepting this presentation, a Recipient agrees that if it proceeds further with its investigations, consideration or evaluation of investing in CurveBeam it will not in any way rely upon this document. Neither this presentation nor any of its contents will form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in any transaction nor is it intended to be used as the basis for making an investment decision.

CurveBeam recommends that potential investors consult their professional advisors as an investment in CurveBeam is subject to investment and other known and unknown risks, some of which are beyond the control of CurveBeam or its directors and therefore any investment is considered to be speculative in nature.

## Forward looking statements

The information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of CurveBeam's views on future performance or condition. Past performance cannot be relied upon as an indicator of future performance. This presentation contains certain forward-looking statements. The words "forecast", "estimate", "like", "anticipate", "opinion", "should", "could", "may" and other similar expressions are intended to identify future earnings, financial position and performance of CurveBeam. You are cautioned not to place undue reliance on these statements. These forward-looking statements are based on estimates, projections and assumptions made by CurveBeam about circumstances and events that have not yet taken place. Although due care and attention has been used in the preparation of these statements, such forward-looking statements are based on numerous assumptions regarding CurveBeam's present and future business strategies and the political, regulatory and economic environment in which CurveBeam will operate in the future and are subject to change without notice. Statements about market and industry trends, which are based on interpretations of current market conditions, may not be reasonable, and are not guarantees or predictions of future performance.


The actual results or performance of CurveBeam may be materially different from the results or performance expressed or implied by such forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including any of the Limited Parties). In particular, no representation, warranty or assurance (express or implied is given that the occurrence of the events expressed or implied in any forward-looking statement in this presentation will actually occur). Subject to any continuing obligations under applicable law, the Company expressly disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statement or any change in events, conditions or circumstances on which any statement is based.

## Financial information

All numbers in this presentation are stated in Australian dollars (**A\$**) unless stated otherwise.

# INVESTMENT HIGHLIGHTS

Combining Weight Bearing CT (WBCT) imaging equipment with AI solutions to target faster, more efficient point of care clinical assessment aids in orthopaedics & bone health



## CurveBeam AI's HiRise Weight bearing CT



### First to market

Natural bilateral WBCT & Non WBCT, point of care imaging with targeted proprietary AI solutions

### Advanced Regulatory

FDA cleared, TGA & CE marked CT imaging equipment. Targeting regulatory submissions for AI modules

### Favourable US Reimbursement in Place

Coding, payment & coverage under existing policies

### Large Market Opportunities

Large billion-dollar addressable markets

### US partnership established with market leader

Co-marketing & distribution agreement with Stryker Corporation US Foot & Ankle division (NYSE:SYK)

### Growing sales

A\$11.48m FY23 revenue (Unaudited), circa 55% growth – CT footprint key to building SaaS annuity from AI modules with circa ~90% GP

### KOL & Clinical Validation

Key KOL sites as users – Mayo, Duke, HSS  
10 years of publications on bone fragility & WBCT

### Experienced board & management


with supportive institutional investors - **Karst Peak, Tenmile, Firetrail, Acorn, SG Hiscock, Ilwella, Frazis Capital**

### Building IP position

37 granted patents and 27 pending patents internationally

---

# HIRISE IN ACTION (VIDEO)



# CURVEBEAM AI CT DEVICES & AI SOLUTIONS

CurveBeam AI has a range of CT imaging devices with visualisation applications in orthopaedics and bone health. CurveBeam AI's imaging devices have regulatory clearances and will provide the platform for the company's AI modules (post regulatory clearances)



## ORTHOPAEDIC VISUALISATION & PLANNING

## BONE HEALTH CLINICAL AIDS (target commercialisation - FY26 US Capitated market)

**ADVANCED CT IMAGING SYSTEMS**  
(FDA, CE Mark and ARTG cleared)



**HiRise™**  
Weight Bearing CT imaging



**InReach™**  
HR-pQCT  
High resolution wrist scanning for Bone microstructural assessment

### IMPROVED FX DETECTION

35% improved simple fracture detection rate and 2-fold improved identification of complex fracture over x-ray

### LOW RADIATION DOSE

Up to 66% less Radiation exposure than conventional CT scanners

### REVENUE GENERATING

Existing favourable reimbursement creates an attractive financial model for WBCT users

### MULTI-EXTREMITY SOLUTION

HiRise is the first product capable of natural bilateral WBCT from hip to foot


### POINT OF CARE

Smaller and lower cost hardware which requires limited radiation shielding enables imaging systems to be placed at Point of Care locations


**AI SOLUTIONS**  
(subject to FDA clearance)



CubeVue Autometrics



Bone Mineral Density




OssView (SFS)

\* Does not include all CurveBeam AI products




# WEIGHT BEARING CONE BEAM CT FOR TOTAL ALIGNMENT

- ✓ **Quicker and easier** to scan than traditional CT and MRI, with faster image acquisition time
- ✓ **High resolution** and **3D visualisation** enables development of new AI based assessment tools
- ✓ **Radiation dose lower** than traditional CT – up to 66% less than traditional CT
- ✓ **Smaller and lower-cost hardware** requiring limited radiation shielding infrastructure



## Hip to Foot in standing 3D

HiRise is the first product capable of WBCT of hip to foot in standing 3D



## Weight bearing imaging key to accurate diagnosis

WBCT provides unique alignment data required to accurately assess bone positioning under standing load




## Serves more applications

The HiRise serves various orthopaedic sub-specialties in total knee, hip and ankle replacement planning in addition to implant manufacturers and 3D printed solution providers

# LAND & EXPAND COMMERCIALISATION STRATEGY

With over 170 first & second-generation installations worldwide, CurveBeam AI is well placed to upgrade its global install base to the HiRise for targeting high margin AI module revenue

- CurveBeam AI utilises a combination of specialist distributors and direct salesforce to drive global sales
- Fast growing sales pipeline to build on over 170 existing installations worldwide
- 38 HiRise units placed since FDA clearance in late 2020. Circa 75% of placements in the US market
- Targeting an installed base of HiRise systems across key global markets including the US and Germany
- Targeting commencement of SaaS revenue from AI modules by late FY25





# LARGE MARKET OPPORTUNITY AND ONGOING ADOPTION BY LEADING CUSTOMERS

CurveBeam AI's target customer groups	Potential US WBCT Installation Sites <sup>1</sup>	Potential US Addressable Market <sup>2</sup>	Select CurveBeam AI customers
<b>Orthopaedic Surgeons &amp; Group Practices</b> Surgeon group practices that have imaging capability	<b>5,829</b>	<b>A\$3.6b</b>	<ul style="list-style-type: none"> <li>• Mayo Clinics (all 3 major locations)</li> <li>• NYU Langone Health</li> <li>• UCLA Orthopedic Institute for Children</li> </ul>
<b>Imaging Chains</b> Orthopaedic Diagnosis, Surgical planning, fragility fracture diagnosis & management	<b>&gt;6,000</b>	<b>&gt;A\$3.7b</b>	<ul style="list-style-type: none"> <li>• Kent State University – College of Podiatric Medicine</li> <li>• Duke Orthopedics</li> <li>• Midwest Orthopedics at Rush, Chicago</li> </ul>
<b>Hospital based</b> Medium to large hospitals - can incorporate surgical planning for implants, fractures	<b>5,460</b>	<b>A\$3.4b</b>	<ul style="list-style-type: none"> <li>• Penn Medicine – Pennsylvania Hospital</li> <li>• Hospices Civils De Lyon, France</li> </ul>
<b>Integrated Healthcare Networks (IHN)</b> Imaging departments for today, new Point of Care solutions for the future			<ul style="list-style-type: none"> <li>• Massachusetts General Hospital, Boston</li> <li>• Schön Klinik, Munich, Germany</li> <li>• Hospital for Special Surgery, New York</li> </ul>
<b>Total</b>	<b>&gt;17,352</b>	<b>&gt;A\$10b</b>	<ul style="list-style-type: none"> <li>• Ghent University Hospital, Belgium</li> </ul>

1. Source: Frost & Sullivan

2. US HiRise indicative price US\$410,000 x \$1.50 USD/AUD potential installation sites in the US

# INVESTMENT PROPOSITION FOR SURGEONS

Existing reimbursement codes target an attractive financial model for HiRise users

- The average Medicare reimbursement rate for scans of the lower extremity CPT code relevant to the HiRise™, pedCAT™ and LineUP™ was US\$138.77 per scan in 2022.
- With an initial capital cost of USD\$410,000 and assuming 10 scans per day, the payback period for a HiRise™ (excluding costs) is 1 year and 5 months
- If financed under a lease with an interest rate of 9%, the breakeven number of scans required to pay the machine off over a 5-year term is 2.83 scans per day (excluding costs)



Atlantic Orthopedic Specialists,  
Virginia Beach, VA

**Actual CurveBeam Customer - PedCat**

**Device up front cost:** \$179,000

**Volume:** 35 scans per month

**Breakeven:** 17 scans/month

**Reimbursement range:** \$99.74 to \$294.3<sup>1</sup>

**Average reimbursement:** \$242.11

Gross revenue / month: \$7014.08

**Device payback period of 2.5 years**

1. US Payment and coverage varies extensively city to city, state to state and this example represents a specific model for a specific region of the US market

# STRYKER FOOT & ANKLE CO-MARKETING & DISTRIBUTION US PARTNERSHIP

Stryker is a market leader in orthopaedics with US\$18b in sales in FY22.



## STRYKER CORPORATION (NYSE:SYK) BACKGROUND

- Leading multinational medical technology company - Orthopaedics & Spine contributes circa 55% of Stryker's US\$18b sales
- CurveBeam AI Agreement is with Foot & Ankle division at this point
- Stryker have several large product categories in Orthopaedics, including Foot and Ankle and Joint Replacement
- HiRise units will be preloaded with Stryker Prophecy surgical CT planning protocols for surgeon office setting. Prophecy preoperative navigation reports and guides are patient-specific tools for total ankle
- Stryker Mako – Number one surgical robotic system in knee and hip. The Mako System offers three applications for Partial Knee, Total Hip, and Total Knee procedures
- Mako's 3D CT-based printing system can provide a customised virtual model for a patient's unique joint but needs a CT scan. HiRise, is targeting surgeon office access for this CT requirement and the company is targeting to validate this functionality

# STRYKER CO-MARKETING & DISTRIBUTION PARTNERSHIP

US Foot & Ankle agreement only at this point.



Stryker Foot & Ankle products

## CURVEBEAM AI & STRYKER PARTNERSHIP

- US Co-marketing & Distribution partnership - Stryker Foot & Ankle Division
- HiRise will be Stryker's first imaging solution for the Foot & Ankle division
- In May 2023, Stryker Foot & Ankle launched its HiRise promotion, distribution and financing program. This includes access to Stryker's financing options for customers
- Group Surgeon settings – estimated CT usage for F&A (30%) and knee/hip (70%) – MAKO would represent a major driver of CT scans. Prophecy is already validated; the company is now targeting MAKO validation off HiRise. A key target for HiRise placements is the group surgeon practice with hip, knee, and F&A specialists.
- HiRise v2.0 – an upgraded energy source HiRise, due for launch in FY24, is targeting WBCT validated protocols for both systems for the surgeon group practice setting – offering HiRise CT scans for customized datasets for a patient's joint

# BONE HEALTH: CURRENT BONE HEALTH DIAGNOSTIC (DEXA) MISSES THE MAJORITY OF FRAGILITY FRACTURES


Bone fragility is caused by loss of bone microstructure, BMD measures only bone density & not microstructure

## BONE MINERAL DENSITY (BMD): CURRENT STANDARD OF CARE

Commonly administered, limited performance



DEXA: Dual-energy X-ray is a means of measuring bone mineral density (BMD).



It basically looks at a silhouette of bone for determining density, as compared to a normal healthy population.

Small changes in bone density can mask major microstructural changes in the cortical and trabecular bones

## BONE MICROSTRUCTURE




3 electron micrographs – a normal bone density control & female patients of age

- Note - loss of bone microarchitecture is associated with aging
- While loss of bone density contributes to fragility, the major cause of fragility is loss of microstructure
- Bone loss may reduce BMD modestly & it can mask major microstructural changes

# BMD AND OSSVIEW OVERVIEW

CurveBeam AI's proprietary SaaS solutions leverage CT scans generated from its HiRise device

HiRise a change agent




HiRise



## BONE MINERAL DENSITY

- AI driven BMD report utilising CurveBeam AI's high resolution CT scans for BMD (hip) & bone microstructure (ankle) assessment. Possible only on the HiRise
- Under development - target FDA 510(k) filing in FY24
- On FDA clearance, the company expects to be able to provide BMD reports in conjunction with imaging for total joint replacements, with a goal to prevent revision surgery
- **Favourable reimbursement in place in the US market**

Healthy Bone Patient's Bone



## OssView (SFS)

- AI generated report for aiding physicians in the assessment of fracture risk with non-osteoporotic BMD
- OssView awarded **FDA Breakthrough Device Designation**. Ossview (wrist) with InReach HR-pQCT presently under review by FDA (targeting clearance in FY24)
- Also to be enabled by HiRise (feature under development)
- Company is targeting payment for OssView through 2 programs, 1) under a capitated system clinical validation trial & 2) a fee for service (FFS) payer coverage. The FFS program will target AMA to assign an existing CPT code to Ossview. Coverage and payment to be targeted through clinical trials demonstrating strong health economics of OssView

# AI MODULES ALSO TARGET VALUE ADD SUBSCRIPTIONS ON HIRISE INSTALL BASE

CubeVue AutoMetrics aims to reduce 16 hours of CT dataset preparation prior to pre-surgical planning to a scan available in 15 minutes

"To minimize future predicted costs, morbidity, & mortality from increasing numbers of fragility fractures in our rapidly aging population, the AAOS recommends that bone fragility should become a national public health priority"


- American Association of Orthopedic Surgeons (AAOS)



## THE PROBLEM

### Aids in bone segmentation for accurately identifying key anatomical points

- Orthopaedic pre-treatment planning involves understanding of the structure and alignment of the foot – 26 bones & 33 joints
- To segment the bones in the foot and accurately assess bone geometry & alignment requires ~6 hours of manual effort. Not feasible in practice
- Typically, surgeons will make crude manual measurements on 2D radiographs
- No reimbursement in place at this point




## THE SOLUTION

### CurveBeam AI DLAI segmentation-as-a-service model

- Working 3D model with measurements in minutes for surgeons
- WBCT images drive improvements in accuracy & consistency
- CBAI has several key patents awarded in DLAI & non-AI for bone segmentation
- Targeting this IP for a platform solution for other CT modalities, in addition to WBCT (B2B)
- FDA filing expected in FY2024

# THE CURVEBEAM AI SOLUTION: MICRO-CT + AI IMAGE ANALYSIS PROVIDING BONE MICROSTRUCTURE ASSESSMENT FOR FRACTURE RISK

CurveBeam AI's specialised imaging and the OssView SFS modules are targeting to provide a step change in aiding a clinician in fracture risk assessment, with & without BMD





# SENIOR EXECUTIVE TEAM



**Greg Brown**  
CEO / Managing Director

- B.App.Sc, MBA
- Over 35 years healthcare business experience
- Ex Baxter Diagnostics (Australia & UK), Roche Molecular Systems (Switzerland/New York), Digene Corp (Washington DC/Germany)
- 2006 – 2012 ImpediMed (CEO),
- 2014 – 2022 StraxCorp (Chairman & CEO);
- Board experience: Trinity Biotech (NASDAQ), Immunexpress (IXP), IPD(ASX), UniQuest (UQ)



**Arun Singh**  
Executive Director, COO, CTO,  
US president

- BSc & Masters Degree in Electrical engineering
- Founder, President and Chief Executive Officer of CurveBeam LLC since 2011
- Co-founded Imaging Sciences International (ISI) in 1992. Led development & introduction of I-CAT
- ISI acquired by Danaher Corp. in 2007
- Awarded Lifetime Achievement Award by the AADMRT in 2016 for his visionary contributions to the advancement of cone beam CT



**Ura P Auckland**  
CFO & Company Secretary

- B.Bus, G.Dip Company Secretarial Practice, Columbia University Snr Exec Program 2002. Graduate of CPA program
- Nearly 20 years' experience senior finance, operations and administrative roles in the technology and healthcare sectors
- Previously CFO and Company Secretary of ImpediMed Limited (ASX:IPD) and held various roles at PanBio Limited (ASX:PBO) including CFO, Company Secretary and Vice-President – Point of Care

# EXPERIENCED BOARD



## ROBERT LILLEY

**Chairman, BA (Yale)**

35 years' experience in medical device and diagnostics industry. Previously senior vice president of global sales and marketing, Digene Corporation (Nasdaq:DIGE), a molecular diagnostics company, which was subsequently acquired by Qiagen N.V. (NYSE:QGEN).

Currently Chair of Immunexpress Pty Ltd, an Australian molecular diagnostics company.



## GREGORY BROWN

**Managing Director / CEO, B.app.Sc, MBA**

35 years healthcare experience

Ex Baxter Diagnostics (Australia & UK), Roche Molecular (Switzerland/New York), Digene Corp (Washington DC/Germany)

2006-2012 ImpediMed CEO (IPD:ASX),

2014 – 2022 StraxCorp (Chairman & CEO);

Board experience: Trinity Biotech (NASDAQ), Immunexpress (IXP), IPD(ASX), UniQuest (UQ)



## ARUN SINGH

**Executive Director, COO, CTO-CT, US president**

**BSc & Masters Degree in Electrical Engineering**  
Founder, President and CEO of CurveBeam LLC

Led the development of the first commercially viable Cone Beam CT imaging system for dental and maxillofacial imaging, with 9,000+ systems deployed today globally.

Awarded Lifetime Achievement Award by the AADMRT in 2016 for his visionary contributions to the advancement of cone beam CT



## HASHAN DE SILVA

**Non-Executive Director, BSc (Medicine), MCom, CFA charterholder**

Founder and Managing Partner of KP Rx, a specialist healthcare fund manager.

Previously head of healthcare research at Karst Peak Capital, equity research analyst in healthcare at CLSA Limited and Senior Research Associate Analyst at Macquarie Group.

Director Pharmaxis Limited (ASX:PXS)



## KATE ROBB

**Non-Executive Director BBus (Accounting), CA, GAICD**

25 years' finance, governance, risk management and compliance experience.

Previous senior audit and risk roles at United Energy Limited (ASX:UEL), AGL Energy, ANZ

Non-Executive Director Solvar Ltd (ASX:SVR), chair SVR audit and risk committee and a member of SVR nominations and remuneration committee.

# INVESTMENT SUMMARY

CurveBeam AI produces and sells market leading weight bearing CT scanners. The Company has established key recognised clinical customers and a leading vendor partner.

<b>Regulatory Clearances</b>	First to market, FDA cleared, TGA and CE Marked Point of Care Weight Bearing and high resolution Cone Beam CT imaging equipment
<b>Significant addressable market</b>	Large A\$10b plus A\$4.1b per annum addressable markets
<b>Commercial stage</b>	Commercial stage company with A\$11m forecast revenue for FY2023
<b>Favourable Reimbursement</b>	Favourable reimbursement for CT scans (US/Germany) and BMD HiRise targeted annuity (US only)
<b>Tier 1 Partnership</b>	Distribution partnership with the foot and ankle division of Stryker (NYSE:SYK) to aid in driving growth
<b>Established global footprint</b>	170+ Device placements worldwide including top tier institutions – e.g. Mayo, Duke, HSS 38 HiRise placements since FDA clearance in late 2020
<b>High margin AI solutions</b>	Installed CT devices to underpin incremental high margin AI module revenues commencing late FY25
<b>A\$25m IPO</b>	IPO proceeds to fund US sales growth and key new product development

---

# KEY INVESTMENT RISKS

## Regulatory clearances

- The Group will require, and intends to apply for, further regulatory clearances in key jurisdictions (e.g. USA FDA) to execute its business plan. If current applications are unsuccessful, the Group might need to lodge a subsequent request with the FDA, which could extend the clearance process by 2 to 3 years and in turn could impact the ability of the Company to grow its longer-term business and delay any potential revenues generated by OssView™.
- Regulatory clearance processes are expensive, time consuming and have uncertain outcomes. No assurance can be given that the Group will obtain all clearances or targeted claims and that such clearances will not be subject to significant limitations.

## Regulatory compliance

- The Group's existing cleared products and future cleared products will be subject to continual review and periodic inspections by regulatory agencies.
- Potentially costly follow-ups or post-marketing clinical studies may be required, and previously unknown problems may result in restrictions on the sale and marketing, and possibly the withdrawal from sale of previously cleared products.
- If the Group fails to comply with applicable regulatory requirements, relevant regulatory agencies may take a range of actions against the Group.

## Reimbursement availability

- The commercial success of the Group's products and services is critically dependent on the availability and amounts of available reimbursement. Without reimbursement, or an adequate level of reimbursement, there is little to no incentive for medical providers (and their patients) to use the Group's products and services.
- In the future, the Group may need to implement a specific reimbursement strategy related to its clinical assessment SaaS modules (which can be a lengthy process). No assurance can be given that reimbursement will be provided at all, or that the reimbursement will be adequate for the Group's products and tools.

## Development risk

- An important aspect of the Group's business is to continue to invest in innovation and related product development opportunities. CT product and software development is expensive and inherently risky and products and solutions in development may not meet design objectives or be successful in either pre or post-clinical testing. It often takes many years to develop medical software and CT devices to a point where there is a saleable product for economic, technical and/or regulatory reasons. Accordingly, even when such work is successful, it can be many years before the Group earns a return on its investment.

## Market acceptance

- Sales of the Group's products and services depends on the extent to which they are accepted by the market and the level of competitor activity. There is a risk that the Group's existing devices, and next generation devices, and future products may not gain targeted levels of market acceptance.

## Adoption of SaaS diagnostic solutions

- The Group's long term revenue and profit growth is highly dependent on the utilisation of its SaaS based clinical assessment aids. It may be difficult to persuade some customers to change existing legacy on-premises and manual solutions, and adopt SaaS-based clinical assessment solutions like the Group's products.

## Protection of IP

- If the Group is unable to protect its IP, its competitors could develop and market products and services similar to those of the Group, and demand for the Group's products and services, or the price that the Group is able to charge for such products or services, may decline. Equally, if competitors are successful in obtaining patent protection of technologies relevant to the Group's activities, this may limit the Group's ability to execute its business strategy.

---

# KEY INVESTMENT RISKS

## Additional funding risk

- The Group may need to raise additional funds in the future to support its operations and business. The Group may elect to raise additional funds through the issuance of new equity securities, debt or a combination of both. Additional financing may not be available on favourable terms, or at all, and such financing may be dilutive to Shareholders.

## Key person risk

- There is a risk that the Group may not be able to attract and retain key personnel or be able to find effective replacements for any departures. If the Group's CTO (AI), or CTO (CT) were to leave the Group, the Company would lose significant technical and business expertise which could have an adverse impact on the ability of the Group to implement its planned product development and business strategy.

## Reliance on distributors

- CurveBeam relies on distributors to distribute its products in many markets. The loss of a key distribution relationship, or an underperforming partner, may impact the Group's CT sales and revenue.

## Cyber risk and data breach

- There is a risk that the measures that the Group takes to prevent data breaches may prove to be inadequate which may result in successful cyber-attacks and unauthorised access to or use of data. Any data breaches or other unauthorised access to the Group's information technology systems or sensitive data may result in, among other things, reputational damage, a disruption of services or breaches of obligations under applicable laws or agreements. The Group may also incur costs as a result of rectifying system vulnerabilities or introducing additional safeguards to minimise the risk of data breaches.

## Taxation matters (post-merger)

- The merger agreement includes a mechanism pursuant to which a portion of the consideration payable to the original unitholders in CurveBeam US was withheld to cover potential tax liabilities. There is a risk that potential tax liabilities may exceed the value of this contingent consideration or that tax liabilities arise or are identified after the contingent merger consideration is paid. If additional tax liabilities are identified, the Group would be required to pay such liabilities from its cash reserves. Any such payment will reduce the Group's cash reserves.

# NEXT GENERATION PRODUCT PIPELINE: SKYRISE

- Next generation point of care weight bearing CT imaging platform
- It will cover the spine, neck and shoulder to existing arm and lower extremity imaging.
- Dual CT scanners
- Prototyping stage - Beta site testing targeted for FY25



# SENIOR MANAGEMENT



## **URA P AUCKLAND**

### **CFO, Company Secretary**

B.Bus, G.Dip Company Secretarial Practice, Columbia University Snr Exec Program 2002. Graduate of CPA program

Nearly 20 years' experience senior finance, operations and administrative roles in the technology and healthcare sectors

Previously CFO and Company Secretary of ImpediMed Limited (ASX:IPD) and held various roles at PanBio Limited (ASX:PBO) including CFO, Company Secretary and Vice-President – Point of Care



## **YU PENG**

### **CTO-AI, BSc & PhD**

Over 15 years' experience in computer vision and machine learning and oversees technical strategy and development at CurveBeam, including medical image analysis, machine learning and cloud computing

PhD in Computer Vision and Machine Learning from the University of Newcastle, Australia. Visiting Professor position (honorary) in Artificial Intelligence (AI) at the University of Technology, Sydney, Australia from 2019 to 2022.



## **S. TURNER DEAN**

### **Chief Sales Officer**

45 years of experience in healthcare and software. VP Sales and Director of Business Development for CrossTec Corp., and Executive VP of AZZLY, Inc. Co-founded and sold CrossTec Security (aka Activeworx, Inc.) to Tripwire, Inc. during his tenure at CrossTec Corp. BS in Economics from the University of Wisconsin-Whitewater.



## **VINTI SINGH**

### **Vice President of Marketing, BA (Journalism), MBA**

Over 14 years' communications and marketing experience. Ms Singh joined CurveBeam LLC in 2012 and has served as Vice President of Marketing following the merger of CurveBeam AI and CurveBeam LLC in 2022. Prior to this, Ms Singh was a reporter at the Hearst Connecticut Media Group. Ms Singh has a Bachelor of Journalism and a Masters of Business Administration

 CurveBeam AI

THANK YOU

